Request Demo
Last update 25 Oct 2025
Recombinant human thyroid stimulating hormone(SmartNuclide)
Last update 25 Oct 2025
Overview
Basic Info
Drug Type Hormone |
Synonyms rhTSH (SmartNuclide), 重组人促甲状腺素 (智核生物), SNA 001 + [2] |
Target |
Action agonists |
Mechanism TSHR agonists(Thyroid stimulating hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (02 Apr 2024), |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with Recombinant human thyroid stimulating hormone(SmartNuclide)ChiCTR2500110577
A Prospective Controlled Study on the Efficacy and Safety of Recombinant Human Thyrotropin Injection (rh-TSH) in Postoperative Patients with Differentiated Thyroid Carcinoma (DTC) for Sequential 131I Thyroid Ablation/Metastasis Ablation Therapy Guided by Low-Dose 131I SPECT/CT Precise Evaluation
CTR20192559
评价SNA001在分化型甲状腺癌（DTC）患者术后清甲治疗中安全性和有效性的随机、开放、多中心、对照的Ⅲ期临床试验
[Translation] A randomized, open, multicenter, controlled Phase III clinical trial to evaluate the safety and efficacy of SNA001 in the treatment of postoperative thyroid ablation in patients with differentiated thyroid cancer (DTC)
ChiCTR2100046907
A randomized, open-lable, multicenter, controlled phase III clinical trial to evaluate the safety and efficacy of recombinant human thryoid stimulating hormone (SNA001) in postoperative RAI treatment of differentiated thyroid cancer patients
100 Clinical Results associated with Recombinant human thyroid stimulating hormone(SmartNuclide)
Login to view more data
100 Translational Medicine associated with Recombinant human thyroid stimulating hormone(SmartNuclide)
Login to view more data
100 Patents (Medical) associated with Recombinant human thyroid stimulating hormone(SmartNuclide)
Login to view more data
100 Deals associated with Recombinant human thyroid stimulating hormone(SmartNuclide)
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Differentiated Thyroid Gland Carcinoma | China | 02 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| - | - | 307 | tambtdlnar(iuyljzvhkn) = srsyqgltsd uykritowgs (arzingnpcu ) | Non-inferior | 04 Nov 2024 | ||
standard of care | tambtdlnar(iuyljzvhkn) = tayowiikif uykritowgs (arzingnpcu ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free